Today @TNXP announced the extension of its research agreement w/ @KStateResearch to develop TNX-2300, a live-virus vaccine based on a bovine parainfluenza virus vector to protect against #COVID19, and to test the effect of co-expression of the CD40-ligand. https://t.co/odmvFBFdPt
$TNXP announces publication on antiviral #SARSCoV2 inhibitor, TNX-3500, in @JCI_insight. Early studies in vitro show that sangivamycin, TNX-3500's active ingredient, is a potent antiviral against multiple #variants of #SARSCoV2 and potentiates Remdesivir. https://t.co/Y10t1eywT4